High Dose of Erythropoietin Analogue After Cardiac Arrest

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest. To test this hypotheses, the investigators designed a randomized, multicentre, simple blind trial in which all participating patients will be receive usual treatments and 50% of them will also receive a high dose of epoetin alpha (an analogue of erythropoietin) in an "add on" fashion. The main end point will be the proportion of patients in each arm who will reach at day 60 the best level of recovery, using a 5 level score.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Epoetin Alfa

Criteria

Inclusion criteria:

• Age between 18 and 80

• Witnessed out-of-hospital cardiac arrest, presumed of cardiac origin (non asphyxic)

• Time from cardiac arrest and recovery of circulatory activity less than 60 minutes

• Persistent coma after ROSC (Coma Glasgow Scale < 7)

Exclusion criteria:

• Out-of-hospital cardiac arrest with evidence of extra-cardiac cause (trauma, sepsis, acute respiratory insufficiency, asphyxia)

• Previous or chronic treatment with erythropoietin or analogues

• Pregnancy

• Rapidly fatal underlying disease (expected life duration < 6 months)

• No social security